Background: Micro vascular complications of T2DM are associated with severe morbidity, mortality and a huge economic burden. So, there is an important need to identify new biomarker able to identify disease onset and progression and can be used as a therapeutic target for management of these complications. The Aim of this study was to assessment the Serum progranulin level as a biomarker for the presence and severity of retinopathy in type 2 diabetic patients. Patients and Methods: The current case-control study was carried out conducted on (48 type 2 diabetic patients) at the Internal Medicine and ophthalmology out-patient clinic of Zagazig University Hospitals, during the period from May 2019 to October 2019. All patient referred to ophthalmic out-patient clinic for fundal examination by ophthalmologist ,in which diabetic retinopathy was diagnosed, a complete physical examination including the measurement of height, weight, body mass index, and blood pressure (BP) was performed for all patients. Results: The current study showed that there was a high statistical significant increase in serum PGRN level in diabetic patients with retinopathy, there was a statistical significant positive correlation between serum PGRN level with disease duration, urea, creatinine level and urinary ACR of studied retinopathy patients and also there was a high statistical significant increase in serum PGRN level in diabetic patients with proliferative retinopathy. Conclusions: According to our results serum PRGN level could be used as a biomarker for the presence of microvascular retinal complication and to anticipate the severity of diabetic retinopathy in T2DM patients